StockNews.com Downgrades Amicus Therapeutics (NASDAQ:FOLD) to Hold

Amicus Therapeutics (NASDAQ:FOLD – Get Rating) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday.

A number of other research firms also recently issued reports on FOLD. BTIG Research increased their price target on Amicus Therapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday, January 18th. The Goldman Sachs Group raised their target price on shares of Amicus Therapeutics from $10.00 to $11.00 and gave the company a “neutral” rating in a research report on Thursday, March 2nd. Finally, UBS Group upped their price target on shares of Amicus Therapeutics from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Thursday, March 2nd. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Amicus Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $14.75.

Amicus Therapeutics Price Performance

Shares of FOLD stock opened at $11.24 on Friday. The company has a market capitalization of $3.18 billion, a P/E ratio of -13.71 and a beta of 0.82. The company’s 50-day simple moving average is $12.62 and its two-hundred day simple moving average is $11.69. Amicus Therapeutics has a one year low of $5.91 and a one year high of $13.84. The company has a debt-to-equity ratio of 3.19, a current ratio of 3.05 and a quick ratio of 2.88.

Insider Buying and Selling at Amicus Therapeutics

In other news, Director Margaret G. Mcglynn sold 15,000 shares of the company’s stock in a transaction on Friday, January 13th. The stock was sold at an average price of $13.03, for a total transaction of $195,450.00. Following the transaction, the director now directly owns 50,705 shares of the company’s stock, valued at $660,686.15. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, insider David Michael Clark sold 8,493 shares of Amicus Therapeutics stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $12.03, for a total transaction of $102,170.79. Following the completion of the sale, the insider now directly owns 190,203 shares in the company, valued at $2,288,142.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Margaret G. Mcglynn sold 15,000 shares of the company’s stock in a transaction on Friday, January 13th. The shares were sold at an average price of $13.03, for a total value of $195,450.00. Following the completion of the transaction, the director now directly owns 50,705 shares in the company, valued at $660,686.15. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 365,427 shares of company stock valued at $4,583,219. 2.40% of the stock is currently owned by insiders.

Institutional Trading of Amicus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co NY lifted its holdings in shares of Amicus Therapeutics by 4.9% during the fourth quarter. Metropolitan Life Insurance Co NY now owns 16,962 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 797 shares during the period. Pathstone Family Office LLC lifted its stake in Amicus Therapeutics by 0.8% during the 4th quarter. Pathstone Family Office LLC now owns 102,720 shares of the biopharmaceutical company’s stock valued at $1,254,000 after acquiring an additional 809 shares during the period. Amalgamated Bank boosted its holdings in shares of Amicus Therapeutics by 2.0% in the 4th quarter. Amalgamated Bank now owns 45,518 shares of the biopharmaceutical company’s stock valued at $556,000 after acquiring an additional 899 shares during the last quarter. MetLife Investment Management LLC increased its stake in shares of Amicus Therapeutics by 0.7% in the fourth quarter. MetLife Investment Management LLC now owns 146,423 shares of the biopharmaceutical company’s stock worth $1,788,000 after acquiring an additional 947 shares during the period. Finally, Van ECK Associates Corp raised its holdings in shares of Amicus Therapeutics by 48.9% during the fourth quarter. Van ECK Associates Corp now owns 2,988 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 981 shares during the last quarter.

About Amicus Therapeutics

(Get Rating)

Amicus Therapeutics, Inc operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio.